Frost J J
Alan Guttmacher Institute (AGI), New York.
Fam Plann Perspect. 1994 Jan-Feb;26(1):4-10.
During the first year and a half after the hormonal contraceptive implant became available in February 1991, an estimated 81,100 women obtained this method from family planning agencies in the United States. Nevertheless, according to a recent survey of family planning providers, implant availability through the family planning clinic system is still far from universal. By September 30, 1992, only 40% of all family planning agencies were offering implant services to their clients: That proportion ranged from 30% of health department family planning providers to 80% of Planned Parenthood affiliates. Some of the key reasons cited by agencies that do not yet provide implants include the special clinician training required to learn insertion and removal procedures, and the cost of the method. Furthermore, full accessibility of this method to low-income women attending family planning clinics has been limited primarily to those who receive Medicaid, which has paid for more than 60% of all hormonal implants inserted by family planning agencies.
1991年2月激素避孕植入剂上市后的头一年半时间里，估计有81100名女性从美国计划生育机构采用了这种避孕方法。然而，根据最近对计划生育服务提供者的一项调查，通过计划生育诊所系统提供植入剂的情况仍远未普及。到1992年9月30日，所有计划生育机构中只有40% 为其客户提供植入剂服务：这一比例从卫生部门计划生育服务提供者的30% 到计划生育联合会附属机构的80% 不等。尚未提供植入剂的机构列举的一些关键原因包括，学习植入和取出程序需要临床医生接受专门培训，以及该方法的成本。此外，参加计划生育诊所的低收入女性要完全获得这种避孕方法，主要限于那些接受医疗补助的女性，医疗补助支付了计划生育机构所植入的所有激素避孕植入剂的60% 以上。
